OBJECTIVES: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF). METHODS: Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate. RESULTS: The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. CONCLUSIONS: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment.
OBJECTIVES: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF). METHODS:Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate. RESULTS: The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. CONCLUSIONS: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment.
Authors: Brad Moriyama; Jason Elinoff; Robert L Danner; Juan Gea-Banacloche; Gennethel Pennick; Michael G Rinaldi; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2009-01-26 Impact factor: 5.191
Authors: H J Johnson; Kelong Han; B Capitano; D Blisard; S Husain; P K Linden; A Marcos; E J Kwak; B Potoski; D L Paterson; M Romkes; R Venkataramanan Journal: Antimicrob Agents Chemother Date: 2009-11-23 Impact factor: 5.191
Authors: R J Trof; A Beishuizen; Y J Debets-Ossenkopp; A R J Girbes; A B J Groeneveld Journal: Intensive Care Med Date: 2007-07-24 Impact factor: 17.440